Cyclo Therapeutics rises on FDA nod for Alzheimer's drug trial

Cyclo Therapeutics

06/12/2021 13:32

** Shares of drug developer  CYTH.O  rise 16.5% to $5.56
premarket
    ** Co receives U.S. FDA approval to initiate human mid-stage
trials for its lead drug candidate - Trappsol Cyclo, in treating
early Alzheimer's Disease (AD) (https://refini.tv/3EsGkwU)
    ** Trappsol Cyclo has shown encouraging results to
effectively manage transportation of cholesterol in multiple
clinical studies - CYTH
    ** Co says research suggests cholesterol imbalance is
responsible for amyloid beta and tau accumulation in Alzheimer's
    ** Earlier this year, CYTH also launched a late-stage study
to test Trappsol Cyclo in treating a type of progressive genetic
disorder, Niemann-Pick disease
    ** As of last close, stock had gained ~10% this year
    

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))